Intimation pursuant to Regulation 8(1) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( SEBI PIT Regulations )
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science's Board of Directors approved an amendment to the company's Code of Practices and Procedures for Fair Disclosure of UPSI at a meeting held on July 29, 2025 (11:00 AM to 12:20 PM IST). The amended code is effective from the same date and has been filed under Regulation 8(1) of SEBI's Prohibition of Insider Trading Regulations, 2015. Key changes include formal designation of the CFO as the Chief Investor Relations Officer (CIRO), detailed principles for fair and uniform dissemination of price-sensitive information, a policy framework for sharing UPSI for legitimate purposes (with directors, auditors, advisors, etc.), and maintenance of a Structured Digital Database (SDD) of insiders receiving UPSI. The code was aligned with the company's existing materiality policy under SEBI Listing Regulations and is available on the company website.
This is a routine regulatory compliance update to strengthen insider trading controls and disclosure transparency. No material impact on share price or business operations is expected; it simply reinforces governance around handling of sensitive information.